These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 11134207)

  • 1. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.
    Jaffee EM; Hruban RH; Biedrzycki B; Laheru D; Schepers K; Sauter PR; Goemann M; Coleman J; Grochow L; Donehower RC; Lillemoe KD; O'Reilly S; Abrams RA; Pardoll DM; Cameron JL; Yeo CJ
    J Clin Oncol; 2001 Jan; 19(1):145-56. PubMed ID: 11134207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.
    Lutz E; Yeo CJ; Lillemoe KD; Biedrzycki B; Kobrin B; Herman J; Sugar E; Piantadosi S; Cameron JL; Solt S; Onners B; Tartakovsky I; Choi M; Sharma R; Illei PB; Hruban RH; Abrams RA; Le D; Jaffee E; Laheru D
    Ann Surg; 2011 Feb; 253(2):328-35. PubMed ID: 21217520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.
    Dillman RO; Wiemann M; Nayak SK; DeLeon C; Hood K; DePriest C
    J Immunother; 2003; 26(4):367-73. PubMed ID: 12843799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
    Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
    Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
    J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
    von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
    Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.
    Nemunaitis J; Jahan T; Ross H; Sterman D; Richards D; Fox B; Jablons D; Aimi J; Lin A; Hege K
    Cancer Gene Ther; 2006 Jun; 13(6):555-62. PubMed ID: 16410826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.
    Emens LA; Asquith JM; Leatherman JM; Kobrin BJ; Petrik S; Laiko M; Levi J; Daphtary MM; Biedrzycki B; Wolff AC; Stearns V; Disis ML; Ye X; Piantadosi S; Fetting JH; Davidson NE; Jaffee EM
    J Clin Oncol; 2009 Dec; 27(35):5911-8. PubMed ID: 19805669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine.
    Abou-Alfa GK; Chapman PB; Feilchenfeldt J; Brennan MF; Capanu M; Gansukh B; Jacobs G; Levin A; Neville D; Kelsen DP; O'Reilly EM
    Am J Clin Oncol; 2011 Jun; 34(3):321-5. PubMed ID: 20686403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.
    Chen G; Gupta R; Petrik S; Laiko M; Leatherman JM; Asquith JM; Daphtary MM; Garrett-Mayer E; Davidson NE; Hirt K; Berg M; Uram JN; Dauses T; Fetting J; Duus EM; Atay-Rosenthal S; Ye X; Wolff AC; Stearns V; Jaffee EM; Emens LA
    Cancer Immunol Res; 2014 Oct; 2(10):949-61. PubMed ID: 25116755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.
    Simons JW; Jaffee EM; Weber CE; Levitsky HI; Nelson WG; Carducci MA; Lazenby AJ; Cohen LK; Finn CC; Clift SM; Hauda KM; Beck LA; Leiferman KM; Owens AH; Piantadosi S; Dranoff G; Mulligan RC; Pardoll DM; Marshall FF
    Cancer Res; 1997 Apr; 57(8):1537-46. PubMed ID: 9108457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
    J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study.
    Mahvi DM; Shi FS; Yang NS; Weber S; Hank J; Albertini M; Schiller J; Schalch H; Larson M; Pharo L; Gan J; Heisey D; Warner T; Sondel PM
    Hum Gene Ther; 2002 Sep; 13(14):1711-21. PubMed ID: 12396624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting.
    Lipson EJ; Sharfman WH; Chen S; McMiller TL; Pritchard TS; Salas JT; Sartorius-Mergenthaler S; Freed I; Ravi S; Wang H; Luber B; Sproul JD; Taube JM; Pardoll DM; Topalian SL
    J Transl Med; 2015 Jul; 13():214. PubMed ID: 26143264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
    Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
    Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
    Salgia R; Lynch T; Skarin A; Lucca J; Lynch C; Jung K; Hodi FS; Jaklitsch M; Mentzer S; Swanson S; Lukanich J; Bueno R; Wain J; Mathisen D; Wright C; Fidias P; Donahue D; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Sugarbaker D; Mihm M; Dranoff G
    J Clin Oncol; 2003 Feb; 21(4):624-30. PubMed ID: 12586798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma.
    Powell A; Creaney J; Broomfield S; Van Bruggen I; Robinson B
    Lung Cancer; 2006 May; 52(2):189-97. PubMed ID: 16563560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential administration of GM-CSF (Sargramostim) and IL-2 +/- autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial.
    Elias EG; Zapas JL; McCarron EC; Beam SL; Hasskamp JH; Culpepper WJ
    Cancer Biother Radiopharm; 2008 Jun; 23(3):285-91. PubMed ID: 18593361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.